Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma.

Blood
Mehdi HamadaniBrad Kahl

Abstract

The prognosis for patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL) remains poor, with a need for alternatives to current salvage therapies. Loncastuximab tesirine (ADCT-402) is an antibody-drug conjugate comprising a humanized anti-CD19 monoclonal antibody conjugated to a pyrrolobenzodiazepine dimer toxin. Presented here are final results of a phase 1 dose-escalation and dose-expansion study in patients with R/R B-NHL. Objectives were to determine the maximum tolerated dose (MTD) and recommended dose(s) for expansion and evaluate safety, clinical activity, pharmacokinetics, and immunogenicity of loncastuximab tesirine. Overall, 183 patients received loncastuximab tesirine, with 3 + 3 dose escalation at 15 to 200 µg/kg and dose expansion at 120 and 150 µg/kg. Dose-limiting toxicities (all hematologic) were reported in 4 patients. The MTD was not reached, although cumulative toxicity was higher at 200 µg/kg. Hematologic treatment-emergent adverse events were most common, followed by fatigue, nausea, edema, and liver enzyme abnormalities. Overall response rate (ORR) in evaluable patients was 45.6%, including 26.7% complete responses (CRs). ORRs in patients with diffuse large B-cell lymphoma (DLBCL), m...Continue Reading

References

Aug 1, 1995·Leukemia & Lymphoma·R H Scheuermann, E Racila
Feb 24, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J M VoseR I Fisher
Jun 16, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Laurie H SehnJoseph M Connors
Feb 25, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Igor PuzanovMace L Rothenberg
Apr 5, 2011·Expert Opinion on Investigational Drugs·John A Hartley
Jun 2, 2012·Expert Opinion on Biological Therapy·John R AdairKerry A Chester
Dec 6, 2012·Experimental Hematology & Oncology·Kemeng WangDelong Liu
Aug 13, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruce D ChesonT Andrew Lister
May 21, 2015·American Society of Clinical Oncology Educational Book·Grzegorz S Nowakowski, Myron S Czuczman
Mar 18, 2017·Nature Reviews. Drug Discovery·Alain BeckNathalie Corvaïa
Dec 7, 2018·The New England Journal of Medicine·Stephen J SchusterUNKNOWN JULIET Investigators
Jan 9, 2019·CA: a Cancer Journal for Clinicians·Rebecca L SiegelAhmedin Jemal
Jan 18, 2019·American Journal of Hematology·Adam Levin, Nirav N Shah
Feb 1, 2019·Blood·Carla Casulo, Paul M Barr
Jun 12, 2019·CA: a Cancer Journal for Clinicians·Kimberly D MillerRebecca L Siegel
Jul 28, 2019·Journal of Hematology & Oncology·Sabarish Ayyappan, Kami Maddocks
Nov 7, 2019·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Brad S KahlOwen A O'Connor
Nov 7, 2019·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Laurie H SehnMatthew J Matasar

❮ Previous
Next ❯

Citations

Mar 4, 2021·The New England Journal of Medicine·Laurie H Sehn, Gilles Salles
Apr 7, 2021·Blood Cancer Journal·Bruce D ChesonGilles Salles
May 14, 2021·Blood·Andrew McMillan
May 28, 2021·Biologics : Targets & Therapy·Mattia NovoUmberto Vitolo
May 22, 2021·Cancer Management and Research·Thomas A Ollila, Adam J Olszewski
Jun 7, 2021·Journal of Hematology & Oncology·Yurou ChuXin Wang
Jun 19, 2021·Drugs·Arnold Lee
Aug 7, 2021·Blood and Lymphatic Cancer : Targets and Therapy·Georgios Pongas, Bruce Cheson
Aug 7, 2021·International Reviews of Immunology·Divya Kandari, Rakesh Bhatnagar
Aug 28, 2021·Journal of Clinical Medicine·Jamie L Stokke, Deepa Bhojwani
Sep 11, 2021·Expert Opinion on Biological Therapy·Krishna Goparaju, Paolo F Caimi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.